

Chairs:  
**Pietro Lampertico and Heiner Wedemeyer**

*program*

**OCTOBER**  
**11-12, 2024**  
**MILAN, ITALY**

Fondazione Cariplo - Conference Center

**Delta** *care*

**3<sup>rd</sup> International Meeting**

with the support of



UNIVERSITÀ  
DEGLI STUDI  
DI MILANO



abstract deadline  
**July 29, 2024**

*also-online*  [www.deltacure2024.com](http://www.deltacure2024.com)

# Dear Colleagues and Friends,

It's a great pleasure to invite you to the 3<sup>rd</sup> Edition of **Delta Cure International Meeting** to be held in **Milan, Italy**, on **October 11-12, 2024**.

We are organizing an exciting meeting in a hospitable environment that will certainly favor an important scientific exchange. Infact, the **Delta Cure Meeting** will review the last evidences in terms of virology, pathogenesis and epidemiology, diagnosis and endpoints.

Two full sessions will be dedicated to thoughtfully debate the most recent advances in terms of current and new antiviral treatments. We will also discuss suggestions for treatment algorithms which will be included in a meeting report to be published in a leading journal of the field. The Faculty will involve an excellent panel of Experts who will guide the attendees through all the challenges of this disease. In particular, we want to encourage young scientists to contribute in topical scientific sessions by submitting abstracts.

Milan is a vibrant cosmopolitan center where the various cultures of northern European and Mediterranean countries merge; it has a lot to offer: art museums, history, opera (La Scala), music, fashion, design, culinary delights and business opportunities. Milan is easy to reach by all means of transport, but is one of the most accessible cities in Europe in terms of air links through 3 international airports (Malpensa, Linate and Orio al Serio).

Furthermore, Milan has the largest public transport network which let people travel around the city urban community and the region easily and quickly.

This event will give you the opportunity to focus on the newest scientific trends in our field in an atmosphere of Italian hospitality and the Italian expression of European Union.

We are sure that - forty-five years after the discovery of HDV - this Meeting will shed new exciting lights on the management of this difficult-to-treat disease.

**Looking forward to meeting you in October 2024,**

**Arrivederci in Milan!**

The Chairs  
*Pietro Lampertico and Heiner Wedemeyer*



# Faculty

**Kosh Agarwal** - King's College Hospital, London (UK)

**Soo Aleman** - Karolinska University Hospital, Huddinge (Sweden)

**Lena Allweiss** - University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

**Maria Paola Anolli** - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

**Tarik Asselah** - Hôpital Beaujon, APHP, Clichy, France, University of Paris, Paris (France)

**Thomas Berg** - University Hospital Leipzig, Leipzig (Germany)

**Maurizia Brunetto** - Azienda Ospedaliero Universitaria Pisana, Università degli Studi di Pisa, Pisa (Italy)

**Maria Buti** - Hospital General Universitari Valle Hebron, Barcelona (Spain)

**Isabelle Chemin** - Cancer Research Center, Lyon (France)

**Marcelo Contardo Naveira** - WHO Regional Office for Europe, Copenhagen (Denmark)

**Harel Dahari** - Loyola University Medical Center, Chicago (USA)

**Maura Dandri** - University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

**Elisabetta Degasperi** - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

**Gianpiero D'Offizi** - Istituto Nazionale di Malattie Infettive "Lazzaro Spallanzani", Rome (Italy)

**Rafael Esteban** - Hospital Universitario Val d'Hebron, Universidad Autonoma de Barcelona, Barcelona (Spain)

**Hélène Fontaine** - Assistance Publique Hopitaux de Paris, Paris (France)

**Saeed Sadiq Hamid** - The Aga Khan University, Karachi (Pakistan)

**Mathias Jachs** - Medical University of Vienna, Vienna (Austria)

**Helenie Kefalakes** - Hannover Medical School, Hannover (Germany)

**Pietro Lampertico** - IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan (Italy)

**Julie Lucifora** - Centre International de Recherche en Infectiologie, Lyon (France)

**Niklas Luhmann** - WHO Headquarters, Geneva (Switzerland)

**Erkin Musabaev** - Research Institute of Virology, Tashkent (Uzbekistan)

**George Papatheodoridis** - "Laiko" General Hospital of Athens, Athens (Greece)

**Nancy Reau** - Rush University Medical Center, Chicago (USA)

**Francesco Paolo Russo** - University Hospital Padova, Padova (Italy)

**Lisa Sandmann** - Hannover Medical School, Hannover (Germany)


**Barbara Testoni** - Cancer Research Center of Lyon, Lyon (France)

**Stephan Urban** - Heidelberg University Hospital, Heidelberg (Germany)

**Heiner Wedemeyer** - Hannover Medical School, Hannover (Germany)

**Cihan Yurdaydin** - Koç University Medical School, Istanbul (Turkey)

**Fabien Zoulim** - Hospices Civils de Lyon, Lyon (France)



**Opening Session**

11.20 - 11.30 **Welcome by Chairs** *P. Lampertico and H. Wedemeyer*

**WHO SESSION Hepatitis Delta: making a difference in low- and middle-income countries**

*Moderators: M. Naveira and F.P. Russo*

11.30 - 11.40 **Updated WHO HBV guidelines and recommendations for testing and diagnosis for HDV**  
*N. Luhmann*

11.40 - 11.50 **Diagnostics for HDV: what we have and what we need for improving diagnosis in low-and-middle income countries** *I. Chemin*

11.50 - 12.00 **Hepatitis Delta epidemiology and experiences with HDV diagnosis and reflex testing in Uzbekistan** *E. Musabaev*

12.00 - 12.15 **HDV diagnosis and treatment in Pakistan and the way forward for LMICs** *S.S. Hamid*

12.15 - 12.30 **Panel discussion**

12.30 - 13.30 **Light Lunch and poster viewing**

**SESSION 1 Virology, Pathogenesis and Diagnosis**

*Moderators: M. Dandri and J. Lucifora*

13.30 - 13.50 **Virology: the latest insights** *S. Urban*

13.50 - 14.10 **Pathogenesis: insights from liver biopsies** *L. Allweiss*

14.10 - 14.30 **Are immune responses important in HDV infection?** *H. Kefalakes*

14.30 - 14.50 **New HBV biomarkers: any role in HDV?** *B. Testoni*

14.50 - 15.00 **Oral presentation (selected abstract)**

15.00 - 15.20 **Discussion**

15.20 - 15.50 **Coffee Break and poster viewing**



# OCTOBER 11, 2024

OCTOBER  
11-12, 2024  
MILAN, ITALY

# Delta Cure

3<sup>rd</sup> International Meeting

## SESSION 2

### Diagnosis, staging, HCC risk and antiviral therapy

*Moderators: S. Aleman and R. Esteban*

- 15.50 - 16.10 HDV-RNA assays: performances and clinical challenges *M.P. Anolli*
- 16.10 - 16.30 Fibroscan and other non-invasive markers *L. Sandmann*
- 16.30 - 16.50 PegIFN+NUC: predictors of response *M. Brunetto*
- 16.50 - 17.00 Oral presentation (selected abstract)
- 17.00 - 17.20 Discussion

## SESSION 3

### Current and new antiviral treatments I

*Moderators: G. Papatheodoridis and N. Reau*

- 17.20 - 17.40 Bulevirtide mono and combo in clinical trials *H. Wedemeyer*
- 17.40 - 17.55 Bulevirtide in EU: SAVE-D study update *E. Degasperi*
- 17.55 - 18.10 Bulevirtide in France: multicenter study update *H. Fontaine*
- 18.10 - 18.25 Bulevirtide for decompensated cirrhosis *M. Jachs*
- 18.25 - 18.35 Oral presentation (selected abstract)
- 18.35 - 19.00 Discussion
- 19.00 - 19.30 State of the Art Lecture and Prize: "My journey with HDV" *C. Yurdaydin*  
*(presented by H. Wedemeyer)*
- 19.30 - 20.00 Transfer to the Dinner venue *(walking distance)*
- 20.00 - 22.30 Apero and Dinner



08.30 - 08.50 Opening remarks Day 2 *P. Lampertico and H. Wedemeyer*

**SESSION 4** **Current and new antiviral treatments II**

*Moderators: T. Berg and M. Buti*

08.50 - 09.10 Bulevirtide in HIV coinfecting patients *G. D'Offizi*

09.10 - 09.30 Can we stop Bulevirtide? Lessons learned from viral kinetics modelling *H. Dahari*

09.30 - 09.50 What have we learned from the Lonafarnib and pegIFN lambda trials? *T. Asselah*

09.50 - 10.10 New antivirals for HDV, phase II studies *K. Agarwal*

10.10 - 10.30 What can we learn from HBV trials for HDV cure? *F. Zoulim*

10.30 - 10.40 Oral presentation (selected abstract)

10.40 - 11.00 Discussion

11.00-11.30 Coffee Break and poster viewing

**SESSION 5** **Round Table Discussion**

*Moderators: P. Lampertico and H. Wedemeyer*

11.30 - 12.30 Hot topics in HDV management.

Academia, Pharma, Diagnostics, Patient Associations

12.30 - 12.45 Closing remarks *P. Lampertico and H. Wedemeyer*

12.45 - 13.45 Farewell Lunch



## Chairs

Pietro Lampertico  
IRCCS Cà Granda Ospedale Maggiore Policlinico,  
Università degli Studi di Milano, Milan (Italy)

Heiner Wedemeyer  
Hannover Medical School, Hannover (Germany)

## Scientific Secretariat and Abstract Reviewers

Elisabetta Degasperi  
IRCCS Cà Granda Ospedale Maggiore Policlinico,  
Milan (Italy)

Lisa Sandmann  
Hannover Medical School, Hannover (Germany)

OCTOBER  
11-12, 2024  
MILAN, ITALY

DeltaCure  
3<sup>rd</sup> International Meeting

Congress venue  
Fondazione Cariplo - Conference Center  
Via Romagnosi, 8 - 20121 Milan, Italy

CME Provider & PCO  
Effetti srl  
Via G.B. Giorgini 16 - 20151 Milan, Italy  
Tel. +39 02 3343281 - Fax +39 02 38002105  
E-mail: [deltacure2024@effetti.it](mailto:deltacure2024@effetti.it)  
Ref.: Elena Fiore - E-mail: [elena.fiore@effetti.it](mailto:elena.fiore@effetti.it)

also online  [www.deltacure2024.com](http://www.deltacure2024.com)